{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T22:34:53Z","timestamp":1787870093135,"version":"build-2784847793"},"reference-count":38,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2022,2,20]],"date-time":"2022-02-20T00:00:00Z","timestamp":1645315200000},"content-version":"unspecified","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Agenus Inc."},{"name":"Multiple Myeloma research fund"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2022,1,11]]},"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Cancer-associated neoantigens (neoAg) derived from tumor genomic sequencing and predictive algorithms for mutated peptides are a promising basis for therapeutic vaccines under investigation. Although these are generally designed to bind major histocompatibility complex class I and induce CD8 cytolytic T lymphocyte (CTL) activity, results from preclinical and clinical studies demonstrate that the majority of neoAg vaccines efficiently induce CD4 T helper (Th) responses but not CTL. Despite this, these vaccines have demonstrated clinical efficacy. Therefore, understanding the mechanisms of CD4 + T cell-mediated tumor protection is critical to optimizing this immunotherapeutic strategy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We investigated this phenomenon in the mineral oil-induced plasmacytoma (MOPC).315.BM (MOPC315) mouse model of multiple myeloma, a malignancy of plasma cells. MOPC315 cells express in their lambda chain a unique tumor-specific neoAg, an idiotypic (Id) peptide. We generated a vaccine formulated with this Id peptide fused to a heat shock protein HSC70 binding (HSB) motif co-delivered with poly (I:C). The immunogenicity of the Id-vaccine was measured in splenocytes by ELISpot. Mice were challenged with MOPC315 cells and antitumor immunity was assessed by co-incubating splenocytes and bone marrow mononuclear cells derived from vaccinated mice and controls, with the Id antigen and irradiated MOPC315 cells. The frequency of activated CD4 and CD8 T cells and their phenotype were characterized by flow cytometry.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Id-vaccine efficiently induced antigen-specific CD4 Th activity and antitumor immunity, protecting mice from MOPC315 tumor growth. CD4 cytolytic activity was not detected under these conditions. Polyfunctional CD8 T cells homed to the bone marrow microenvironment of protected mice and preferentially expanded only when restimulated ex vivo with both Id peptide and MOPC315 cells. Protective activity was abrogated by depletion of either CD4 or CD8 lymphocytes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>These results demonstrate that Id-HSB +poly (I:C) vaccine protects against MOPC315 growth by priming Id-specific CD4 Th cells that confer protection against tumor but are not directly cytotoxic. These data indicate that activation of CD8 CTL against MOPC315-associated antigens not present in the vaccine is one of the major mechanisms of tumor immunity.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2021-003572","type":"journal-article","created":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T12:07:54Z","timestamp":1645445274000},"page":"e003572","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":18,"title":["Neoantigen vaccine-induced CD4 T cells confer protective immunity in a mouse model of multiple myeloma through activation of CD8 T cells against non-vaccine, tumor-associated antigens"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2045-386X","authenticated-orcid":false,"given":"Selma","family":"Bekri","sequence":"first","affiliation":[{"name":"Department of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reunet","family":"Rodney-Sandy","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Gruenstein","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Mei","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjarne","family":"Bogen","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine, University of Oslo, Oslo, Norway"},{"name":"Department of Immunology, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8697-8955","authenticated-orcid":false,"given":"John","family":"Castle","sequence":"additional","affiliation":[{"name":"Monte Rosa Therapeutics, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Levey","sequence":"additional","affiliation":[{"name":"Agenus Inc, Lexington, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4481-5757","authenticated-orcid":false,"given":"Hearn Jay","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,2,21]]},"reference":[{"key":"2025100315150594000_10.2.e003572.1","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.clml.2019.08.002","article-title":"SOHO state of the art updates and next questions: T-cell\u2013directed immune therapies for multiple myeloma: chimeric antigen receptor\u2013modified T cells and bispecific T-Cell\u2013Engaging agents","volume":"19","author":"Madduri","year":"2019","journal-title":"Clinical Lymphoma Myeloma and Leukemia"},{"key":"2025100315150594000_10.2.e003572.2","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.m3176","article-title":"Emerging immunotherapies in multiple myeloma","volume":"37","author":"Shah","year":"2020","journal-title":"BMJ"},{"key":"2025100315150594000_10.2.e003572.3","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0686"},{"key":"2025100315150594000_10.2.e003572.4","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2020.101389","article-title":"Tumor-associated O-glycans of MUC1: carriers of the glyco-code and targets for cancer vaccine design","volume":"47","author":"Beckwith","year":"2020","journal-title":"Semin Immunol"},{"key":"2025100315150594000_10.2.e003572.5","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.tranon.2019.02.008","article-title":"Cancer-testis antigen peptide vaccine for cancer immunotherapy: progress and prospects","volume":"12","author":"Wei","year":"2019","journal-title":"Transl Oncol"},{"key":"2025100315150594000_10.2.e003572.6","doi-asserted-by":"publisher","DOI":"10.1038\/nature12213"},{"key":"2025100315150594000_10.2.e003572.7","first-page":"1289","article-title":"Generation of immunity to the HER-2\/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine","volume":"5","author":"Disis","year":"1999","journal-title":"Clin Cancer Res"},{"key":"2025100315150594000_10.2.e003572.8","doi-asserted-by":"publisher","DOI":"10.1084\/jem.187.5.693"},{"key":"2025100315150594000_10.2.e003572.9","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.20.10972"},{"key":"2025100315150594000_10.2.e003572.10","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830161110"},{"key":"2025100315150594000_10.2.e003572.11","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.4049\/jimmunol.138.4.1289","article-title":"Idiotype vaccination against murine B cell lymphoma. Inhibition of tumor immunity by free idiotype protein","volume":"138","author":"Kaminski","year":"1987","journal-title":"J Immunol"},{"key":"2025100315150594000_10.2.e003572.12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.3005"},{"key":"2025100315150594000_10.2.e003572.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1406498"},{"key":"2025100315150594000_10.2.e003572.14","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa1348"},{"key":"2025100315150594000_10.2.e003572.15","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.annonc.2020.05.008","article-title":"Neoantigen prediction and computational perspectives towards clinical benefit: recommendations from the ESMO precision medicine Working group","volume":"31","author":"De Mattos-Arruda","year":"2020","journal-title":"Ann Oncol"},{"key":"2025100315150594000_10.2.e003572.16","doi-asserted-by":"publisher","DOI":"10.1038\/nature22991"},{"key":"2025100315150594000_10.2.e003572.17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00295"},{"key":"2025100315150594000_10.2.e003572.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0800251"},{"key":"2025100315150594000_10.2.e003572.19","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0b013e328358f619"},{"key":"2025100315150594000_10.2.e003572.20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0051892","article-title":"A novel mouse model for multiple myeloma (MOPC315.BM) that allows noninvasive spatiotemporal detection of osteolytic disease","volume":"7","author":"Hofgaard","year":"2012","journal-title":"PLoS One"},{"key":"2025100315150594000_10.2.e003572.21","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.12.5700"},{"key":"2025100315150594000_10.2.e003572.22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0109018","article-title":"Eosinophils and megakaryocytes support the early growth of murine MOPC315 myeloma cells in their bone marrow niches","volume":"9","author":"Wong","year":"2014","journal-title":"PLoS One"},{"key":"2025100315150594000_10.2.e003572.23","doi-asserted-by":"publisher","DOI":"10.1006\/cimm.1993.1100"},{"key":"2025100315150594000_10.2.e003572.24","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1152\/physrev.1972.52.3.631","article-title":"Immunoglobulin-producing tumors and myeloma proteins of mice","volume":"52","author":"Potter","year":"1972","journal-title":"Physiol Rev"},{"key":"2025100315150594000_10.2.e003572.25","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830251114"},{"key":"2025100315150594000_10.2.e003572.26","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20091921"},{"key":"2025100315150594000_10.2.e003572.27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0052398","article-title":"Non-Invasive imaging provides spatiotemporal information on disease progression and response to therapy in a murine model of multiple myeloma","volume":"7","author":"Riedel","year":"2012","journal-title":"PLoS One"},{"key":"2025100315150594000_10.2.e003572.28","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.8155"},{"key":"2025100315150594000_10.2.e003572.29","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1002\/j.1460-2075.1989.tb03599.x","article-title":"Minimum length of an idiotypic peptide and a model for its binding to a major histocompatibility complex class II molecule","volume":"8","author":"Bogen","year":"1989","journal-title":"Embo J"},{"key":"2025100315150594000_10.2.e003572.30","doi-asserted-by":"publisher","DOI":"10.1038\/nature14426"},{"key":"2025100315150594000_10.2.e003572.31","first-page":"3699","article-title":"Idiotype vaccines for non-Hodgkin\u2019s lymphoma induce polyclonal immune responses that cover mutated tumor idiotypes: comparison of different vaccine formulations","volume":"90","author":"Caspar","year":"1997","journal-title":"Am Soc Hematol"},{"key":"2025100315150594000_10.2.e003572.32","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2650"},{"key":"2025100315150594000_10.2.e003572.33","doi-asserted-by":"publisher","DOI":"10.1016\/S0952-7915(01)00297-7"},{"key":"2025100315150594000_10.2.e003572.34","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0901235"},{"key":"2025100315150594000_10.2.e003572.35","doi-asserted-by":"publisher","DOI":"10.1038\/nri724"},{"key":"2025100315150594000_10.2.e003572.36","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3910"},{"key":"2025100315150594000_10.2.e003572.37","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-1322"},{"key":"2025100315150594000_10.2.e003572.38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09078-0"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2021-003572","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T22:15:16Z","timestamp":1759529716000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2021-003572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2,21]]},"published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10.1136\/jitc-2021-003572"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2021-003572","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2]]}}}